＜4425＞ Kudan 3110 +504
The stop is high. An American robot company affiliated with a major Japanese automobile manufacturer has announced that it has decided to sell automatic transport robot products equipped with Kudan's artificial perception technology (KudanSlam). In the United States, demand for industrial automatic transport robots is increasing against the backdrop of rising labor costs, etc. With the adoption of this technology, it is said that the robot company's products will be able to run stably and autonomously in a wider range of environments than before. Details of customers and products will be disclosed in the future.
＜5577＞ IDEMY 1788 +95
Significant backlash. It has been announced that it has been certified as a partner company for NVIDIA's AI startup support program “NVIDIA Inception Program” in the US. A program that supports startup companies through product development, prototyping, market introduction, etc. In the future, it is said that IDEMY will utilize the same program to focus on generative AI areas such as production of generated AI-related content, new product development utilizing generated AI, and generative AI introduction support.
＜2164 ＞ Regional Newspapers 645 +8
Continued growth. It has been announced that limited quantity sales of “musubi (musubi) pretzels” developed in collaboration with Togami Bakery, which has a store in Inzai City, Chiba Prefecture, have begun on the EC site “Chiiki no Gem” of regional newspapers. Aiming for new souvenirs from Inzai City, they thoroughly created products that made use of local voices, such as holding reader questionnaires and tasting parties gathering mom readers living in the same city, and commercialized the four types of plain, salt, miso, and caramel.
＜4588＞ Oncolis 622 0
After high in the morning, turn off the value. It has been announced that the Line-1 inhibitor “OBP-601 (TPN-101),” which our company has signed a worldwide license agreement with TransPoson, has been designated as a fast track against progressive supranuclear palsy (PSP) by the U.S. Food and Drug Administration (FDA). Cooperation with the FDA will be strengthened by designation, and there is a possibility that drug development will be accelerated. As a result of Phase 2 clinical trials against PSP, OBP-601 suppresses inflammation of cranial nerves as a LINE-1 inhibitor and suppresses nerve damage.
＜4166＞ parentheses 760 -42
The sharp decline continued. In order to strengthen fraud countermeasures in cross-border EC, it has been announced that the company's fraudulent order detection service “O-PLUX” has released a correction function for misrepresentation of address information in English notation. It is said that businesses that use O-PLUX etc. will be able to trade with peace of mind even when ordering from overseas. O-PLUX is a cloud service that prevents fraudulent damage such as credit card spoofed orders, fraudulent resale/malicious resale, and unpaid postpaid payments, etc., and automates examination operations.
＜4011＞ HEADWATER 13550 +570
Significant backlash. It has been announced that an industrial edge generation AI solution “LLava Edge Vision” has been developed by utilizing the box PC “SIMATIC IPC BX-35A” of Siemens AG of Germany and the edge computing “NVIDIA Jetson Orin NX 16GB” of NVIDIA in the US. It is said that the same solution will be introduced in collaboration with Siemens and NVIDIA at the “8th AI/Artificial Intelligence EXPO Spring” with the cooperation of Ryoyo Electro (Chuo-ku, Tokyo), which is NVIDIA's primary domestic agent.